Immunomodulatory Drugs

References

• Sheskin, J. Thalidomide in the treatment of lepra reactions.Clin. Pharmacol. Ther. 1965 40 (6), 303–306. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Waters, M F. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum.Lepr. Rev. 1971, 42 (1), 26–42. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Pearson, J M.; Vedagiri, M. Treatment of moderately severe erythema nodosum leprosum with thalidomide—a double-blind controlled trial.Lepr. Rev. 1969, 40 (2), 111–116. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Fabbri, P.; Cardinali, C.; Giomi, B.; Caproni, M. Cutaneous lupus erythematosus: diagnosis and management.Am. J. Clin. Dermatol. 2003, 4 (7), 449–465. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Goker, B.; Goker, H. Current therapy for Behcet's disease.Am. J. Ther. 2002, 9 (5), 465–470. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Davey, P P.; Ashrafian, H. New therapies for heart failure: is thalidomide the answer?QJM 2000, 93 (5), 305–311. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bartlett, J B.; Dredge, K.; Dalgleish, A G. The evolution of thalidomide and its IMID derivatives as anticancer agents.Nat. Rev., Cancer 2004 4 (4), 314–344. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moreira, A L.; Sampaio, E P.; Zmuidzinas, A.; Frindt, P.; Smith, K A.; Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.J. Exp. Med. 1993 6 (177), 1675–1680. [CSA], [CROSSREF]
   Google Scholar
• Keifer, J A.; Guttridge, D C.; Ashburner, B P.; Baldwin, A S. Inhibition of NF-kappa B activity by thalidomide through suppression of NFkappaB kinase activity.J. Biol. Chem. 2001, 276 (25), 22382–22387. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sampaio, E P.; Kaplan, G.; Miranda, A.; Nery, J A.; Miguel, C P.; Viana, S M.; Sarno, E N. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum.J. Infect. Dis. 1993 168 (2), 408–414. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Muller, G W.; Corral, L G.; Shire, M G.; Wang, H.; Moreira, A.; Kaplan, G.; Stirling, D I. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.J. Med. Chem. 1996 39 (17), 3238–3240. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Muller, G W.; Shire, M G.; Wong, L M.; Corral, L G.; Patterson, R T.; Chen, Y.; Stirling, D I. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production.Bioorg. Med. Chem. Lett. 1999 9 (11), 1625–1630. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Marriott, J B.; Clarke, I A.; Dredge, K.; Muller, G.; Stirling, D.; Dalgleish, A G. Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4 + and CD8 + T cells.Clin. Exp. Immunol. 2002 130 (1), 75–84. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wolkenstein, P.; Latarjet, J.; Roujeau, J C.; Duguet, C.; Boudeau, S.; Vaillant, L.; Maignan, M.; Schuhmacher, M H.; Milpied, B.; Pilorget, A.; Bocquet, H.; Brun-Buisson, C.; Revuz, J. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis.Lancet 1998, 352 (9140), 1586–1589. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bartlett, J B.; Michael, A.; Clarke, I A.; Dredge, K.; Nicholson, S.; Kristeleit, H.; Polychronis, A.; Pandha, H.; Muller, G W.; Stirling, D I.; Zeldis, J.; Dalgleish, A G. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.Br. J. Cancer 2004 90 (5), 955–961. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Corral, L G.; Haslett, P A.; Muller, G W.; Chen, R.; Wong, L M.; Ocampo, C J.; Patterson, R T.; Stirling, D I.; Kaplan, G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs which are potent inhibitors of TNF-alpha.J. Immunol. 1999 163 (1), 380–386. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Haslett, P A.; Klausner, J D.; Makonkawkeyoon, S.; Moreira, A.; Metatratip, P.; Boyle, B.; Kunachiwa, W.; Maneekam, N.; Vongchan, P.; Corral, L G.; Elbeik, T.; Shen, Z.; Kaplan, G. Thalidomide stimulates T cell responses and interleukin-12 production in HIV-infected patients.AIDS Res. Hum. Retrovir. 1999 130 (15), 1169–1179., [CSA], [CROSSREF]
   Google Scholar
• Trinchieri, G. Interleukin-12: a cytokine at the interface of inflammation and immunity.Adv. Immunol. 1998 70, 83–243. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gavallo, F.; Carlo, E D.; Quaglin, E.; Jezzi, M.; Strasly, M.; Bussolino, F.; Colombo, M P.; Nanni, P.; Lollini, P L.; Musiani, P.; Forni, G. Prevention by delay: nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice.J. Biol. Regul. Homeost. Agents 2001, 15 (4), 351–358. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gupta, D.; Treon, S P.; Shima, Y.; Hideshima, T.; Podar, K.; Tai, Y T.; Lin, B.; Lentzsch, S.; Davies, F E.; Chouhan, D.; Schlossman, R L.; Richardson, P.; Ralph, P.; Wu, L.; Payvandi, F.; Muller, G.; Stirling, D I.; Anderson, K C. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic implications.Leukemia 2001 15 (12), 1950–1961. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lentzsch, S.; LeBlanc, R.; Podar, K.; Dabies, F.; Lin, B.; Hideshima, T.; Catley, L.; Stirling, D I.; Anderson, K C. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells an angiogenesis in vivo.Leukemia 2003 17 (1), 41–44. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dredge, K.; Marriott, J B.; Macdonald, C D.; Man, H.-W.; Chen, R.; Muller, G W.; Stirling, D.; Dalgleish, A G. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.Br. J. Cancer 2002 87 (10), 1166–1172. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mueller, D L.; Jenkins, M K.; Schwartz, R H. Clonal expansion versus functional clonal inactivation: a co-stimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy.Annu. Rev. Immunol. 1989 7, 445–480. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Haslett, P A.J.; Corral, L G.; Albert, M.; Kaplan, G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8 + subset.J. Exp. Med. 1998, 187 (11), 1885–1892. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Haslett, P A.J.; Hanekom, W A.; Muller, G.; Kaplan, G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8 + T cells in vitro.J. Infect. Dis. 2003 187 (6), 946–955. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dredge, K.; Marriott, J B.; Todryk, S M.; Muller, G W.; Chen, R.; Stirling, D I.; Dalgleish, A G. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.J. Immunol. 2002, 168 (10), 4914–4919. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zeldis, J B.; Williams, B A.; Thomas, S D.; Elsayed, M E. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide.Clin. Ther. 1999 21 (2), 319–330. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kumar, S.; Witzig, T E.; Rajkumar, S V. Thalidomide: current role in the treatment of non-plasma cell malignancies.J. Clin. Oncol. 2004, 22 (12), 2477–2488. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Weber, D. Thalidomide and its derivatives: new promise for multiple myeloma.Cancer Control 2003, 10 (5), 375–383. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Zangari, M.; Barlogie, B.; Anaissie, E.; Saghafifar, F.; Eddlemon, P.; Jacobson, J.; Lee, C.-K.; Thertulien, R.; Talamo, G.; Thomas, T.; Van Rhee, F.; Fassas, A.; Fink, L.; Tricot, G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effests of prophylactic and therapeutic anticoagulation.BJH 2004, 126 (5), 715–721. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Richardson, P G.; Schlossman, R L.; Weller, E.; Hideshima, T.; Mitsiades, C.; Davies, F.; LeBlanc, R.; Catley, L P.; Doss, D.; Kelly, K.; McKenney, M.; Mechlowicz, J.; Freeman, A.; Deocampo, R.; Rich, R.; Ryoo, J J.; Chauhan, D.; Balinski, K.; Zeldis, J.; Anderson, K C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.Blood 2002, 100 (9), 3063–3067. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schey, S A.; Fields, P.; Bartlett, J B.; Clarke, I A.; Ashan, G.; Knight, R D.; Streetly, M.; Dalgleish, A G. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.J. Clin. Oncol. 2004, 22 (16), 3269–3276. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma.N. Engl. J. Med. 1999 341 (21), 1565–1571. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Barlogie, B.; Desikan, R.; Eddlemon, P.; Spencer, T.; Zeldis, J.; Munshi, N.; Badros, A.; Zangari, M.; Anaissie, E.; Epstein, J.; Shaughnessy, J.; Ayers, D.; Spoon, D.; Tricot, G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.Blood 2001 98 (2), 492–494. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yakoub-Agha, I.; Attal, M.; Dumontet, C.; Delannoy, V.; Moreau, P.; Berthou, C.; Lamy, T.; Growbois, B.; Dauriac, D.; Dorvaux, V.; Bay, J O.; Monconduit, M.; Harousseau, J L.; Duguet, C.; Duhamel, A.; Facon, T. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the intergroupe francophone du myélome (IFM).Hematol. J. 2002, 3 (4), 185–192. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Schey, S A.; Cavenagh, J.; Johnson, R.; Child, J A.; Oakervee, H.; Jones, R W. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment.Leuk. Res. 2003 27 (10), 909–914. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tosi, P.; Zamagni, E.; Cellini, C.; Ronconi, S.; Patriarca, F.; Ballerini, F.; Musto, R.; Di Raimondo, F.; Ledda, A.; Lauria, F.; Masini, L.; Gobbi, M.; Vacca, A.; Ria, R.; Cangini, D.; Tura, S.; Baccarani, M.; Cavo, M. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.Haematologica 2002 87 (4), 408–414. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Hus, M.; Dimoszynska, A.; Soroka-Wojtaszko, M.; Jawniak, D.; Legiec, W.; Ciepnuch, H.; Hellmann, A.; Wolska-Smolen, T.; Skotnicki, A.; Manko, J.; for the Polish Multiple Myeloma Study Group. Thalidomide treatment of resistant or relapsed multiple myeloma patients.Haematologica 2001 87 (4), 404–408. [CSA]
   Google Scholar
• Hideshima, T.; Chauhan, D.; Shima, T.; Raje, N.; Davies, R E.; Tai, Y T.; Treon, S P.; Lin, B.; Schlossman, R L.; Richardson, R.; Muller, G.; Stirling, D I.; Anderson, K C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional chemotherapy.Blood 2000, 96 (9), 2943–2950. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kumar, S.; Gertz, M A.; Dispenzieri, A.; Lacy, M Q.; Geyer, S M.; Iturria, N L.; Fonseca, R.; Hayman, S R.; Lust, J A.; Kyle, R A.; Greipp, P R.; Witzig, T E.; Rajkumar, S V. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.Mayo Clin. Proc. 2003, 78 (1), 34–39. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dimopoulos, M A.; Zervas, K.; Kouvatseas, G.; Galani, E.; Grigoraki, V.; Kiamouris, C.; Vervessou, E.; Samantas, E.; Papadimitriou, C.; Economou, O.; Gika, D.; Panayiotidis, P.; Christakis, I.; Anagnostopoulos, N. Thalidomide and dexamethasone combination for refractory multiple myeloma.Ann. Oncol. 2001, 12 (7), 991–995. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Weber, D.; Rankin, K.; Gavino, M.; Delasalle, K.; Alexanian, R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.J. Clin. Oncol. 2003, 21 (1), 16–19. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos, A.; Weber, D.; Rankin, K.; Delasalle, K.; Alexanian, R. Thalidomide and dexamethasone for resistant multiple myeloma.Br. J. Haematol. 2003, 121 (5), 768–771. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz, R.; Gonzalez-Porras, J R.; Hernandez, J M.; Polo-Zarzuela, M.; Sureda, A.; Barrenetxea, C.; Palomera, L.; Lopez, R.; Grande-Garcia, C.; Alegre, A.; Vargas-Pabon, M.; Gutierrez, O N.; Rodriguez, J A.; San Miguel, J F. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.Leukemia 2004, 18 (4), 856–863. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Srkalovic, G.; Elson, P.; Trebisky, B.; Karam, M A.; Hussein, M A. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.Med. Oncol. 2002, 19 (4), 219–226. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dimopoulos, M A.; Zomas, A.; Viniou, N A.; Grigoraki, V.; Galani, E.; Matsouka, C.; Economou, O.; Anagnostopoulos, N.; Panayiotidis, P. Treatment of Waldenstrom's macroglobulinemia with thalidomide.J. Clin. Oncol. 2001 19 (6), 3596–3601., [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Coleman, M.; Leonard, J.; Lyons, L.; Szelenyi, H.; Niesvizky, R. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone.Semin. Oncol. 2003 30 (2), 270–274. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dimopoulos, M A.; Tsatalas, C.; Zomas, A.; Hamilos, G.; Panayiotidis, P.; Margaritis, D.; Matsouka, C.; Economopoulos, T.; Anagnostopoulos, N. Treatment of Waldenstrom's macroglobulinemia with single agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone.Semin. Oncol. 2003; 30, 265–269. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mitsiades, C S.; Mitsiades, M.; McMullan, C J.; Poulaki, B.; Hideshima, T.; Chauhan, D.; Treon, S P.; Rishardson, P G.; Munshi, N C.; Joseph, M. Immunomodulatory thalidomide derivatives have activity against tumor cells from Waldenstrom's macroglobulimemia.Blood 2003, 102 (11), 3360 (Abstr.). [CSA]
   Google Scholar
• Hernandez-Ilizaliturri, F J.; Reddy, N.; Holkova, B.; Czuczman, M S. Addition of immunomodulatory drugs CC5013 or CC4047 to rituximab enhances anti-tumor activity in severe combined immunodeficiency mouse lymphoma model.Clin. Cancer Res.. 2003 11 (16), 5984–5992. [CSA], [CROSSREF]
   Google Scholar
• Kaufmann, H.; Raderer, M.; Wöhrer, S.; Püspök, A.; Bankier, A.; Zielinski, C.; Chott, A.; Drach, J. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.Blood 2004, 104 (8), 2269–2271. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Eisen, T.; Boshoff, C.; Mak, I.; Sapunar, F.; Vaughan, M M.; Pyle, L.; Johnston, S R.; Ahern, R.; Smith, I E.; Gore, M E. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.Br. J. Cancer 2000 82 (4), 812–817. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Reiriz, A B.; Richter, M.; Fernandes, S.; Cancela, A.; Dalla Costa, T.; Di Leone, L.; Schwartsmann, G. A phase II study of thalidomide in patients with metastatic malignant melanoma.Proc. Am. Soc. Clin. Oncol. 2003, 22 (720), 2895 (Abstr.). [CSA]
   Google Scholar
• Hwu, W J.; Krown, S E.; Menell, J H.; Panageas, K S.; Merrell, J.; Lamb, L A.; Williams, L J.; Quinn, C J.; Foster, T.; Chapman, P B.; Livingston, P O.; Wolchok, J D.; Houghton, A N. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.J. Clin. Oncol. 2003, 21, 3351–3356. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Danson, S.; Lorigan, P.; Arance, A.; Clamp, A.; Ranson, M.; Hodgetts, J.; Lomax, L.; Ashcroft, L.; Thatcher, N.; Middleton, M R. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.J. Clin. Oncol. 2003 21 (13), 2551–2557. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Raza, A.; Meyer, P.; Dutt, D.; Zorat, F.; Lisak, L.; Nascimben, F.; du Randt, M.; Kapar, D.; Goldberg, C.; Loew, J.; Dar, S.; Gezer, S.; Venugopal, P.; Zeldis, J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.Blood 2001, 98 (4), 958–965. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zorat, F.; Shetty, V.; Dutt, D.; Lisak, L.; Nascimben, F.; Allampallam, K.; Dar, S.; York, A.; Gezer, S.; Venugopal, P.; Raza, A. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.Br. J. Haematol. 2001 115 (4), 881–894. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Strupp, C.; Germing, U.; Aivado, M.; Misgeld, E.; Hass, R.; Gattermann, N. Thalidomide for the treatment of patients with myelodysplastic syndromes.Leukemia 2002 16 (1), 1–6. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• List, A F.; Kurtin, S.; Roe, D J.; Buresh, A.; Mahadevan, D.; Fuchs, D.; Rimsza, L.; Heaton, R.; Knight, R D.; Zeldis, J B. Efficacy of lenalidomide in myelodysplastic syndromes.N. Engl. J. Med. 2005, 352 (6), 549–557. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Streetly, M.; Gyertson, K.; Kazmi, M.; Zeldis, J.; Schey, S A. Alternate day actimid (CC-4047) is well tolerated and is active when used to treat relapsed/refractory myeloma.ASH Proc. 2004, 332 (Abstr.). [CSA]
   Google Scholar
• Barlogi, B.; Shaughnessy, J.; Tricot, G.; Jacobson, J.; Zangari, M.; Anaissie, E.; Walker, R.; Crowley, J. Treatment of multiple myeloma.Blood 2004, 103 (1), 20–32. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rajkumar, S V.; Hayman, S R.; Lacy, M Q.; Dispenzieri, A.; Hoering, A.; Geyer, S M.; Zeldenrust, S R.; Greipp, P R.; Fonseca, R.; Lust, J A.; Russell, S J.; Kyle, R A.; Witzig, T E.; Gertz, M A. Combination therapy with CC-5013 (Lenalidomide; Revlimid) plus dexamethasone (Rev/Dex) for newly diagnosed multiple myeloma.ASH Proc. 2004, 331 (Abstr.). [CSA]
   Google Scholar
• Liu, Y.; Yohnya, T M.; Figg, W D.; Gulley, J L.; Arlen, P M.; Parker, C.; Fedenko, K.; Chen, C C.; Jones, E.; Dahut, W L. Phase I study of CC-5013 (Revimid), a thalidomide derivative in patients with refractory metastatic cancer.Proc. Am. Soc. Clin. Oncol. 2003 927 (Abstr.). [CSA]
   PubMedGoogle Scholar
• Amato, R J.; Floissac, M.; Knight, R.; Levin, A.; Glode, M.; Crawford, D. Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer (HRPC).Prostate Cancer Symp. 2005 252 (Abstr.). [CSA]
   Google Scholar
• Chapa, P.; Rawat, A.; Amato, R J. Phase II study of CC-5013 in patients (pts) with renal cell cancer (RCC). ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004, 22 (14S), 4761 (Abstr.). [CSA]
   Google Scholar